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Abstract 
Background: Coronary heart disease is the leading cause of death worldwide, arising mainly from 
ischemic heart disease. Currently, the most effective method for reducing mortality in patients 
suffering from a coronary occlusion is rapid reperfusion of the ischemic myocardium. Paradoxically, 
reperfusion per se can also increase cell death, a phenomenon termed lethal reperfusion injury. The 
increased understanding of this mechanism, has led to novel research aiming to develop protective 
interventions against lethal reperfusion injury.   
Objective: The first aim of this study was to investigate whether treatment with insulin, the GSK3β-
inhibitor SB-415286 or the combination of both, conferred cardioprotection in terms of reducing 
infarct size in the isolated ex vivo female heart, when administrated at the onset of ischemic-
reperfusion. Secondly, the involvement of the prosurvival kinase Akt was explored to elucidate the 
intracellular signalling pathways involved in these cytoprotective treatments.                                         
Methods: The effect of the various treatments was assessed using the ex vivo isolated Langendorff 
perfused rat heart model. Female rat hearts underwent 20 minutes of stabilisation, 30 minutes of 
regional ischemia followed by 120 minutes of reperfusion ± insulin (0.3 mU/mL), GSK3β-inhibitor 
(3μM) or insulin+GSK3β-inhibitor treatment for 15 minutes at the onset of reperfusion. 
Measurements of infarct size as percentage of risk area were performed in order to evaluate the 
cardioprotective effect. To explore phosphorylation status of the prosurvival kinase Akt in response 
to the various treatments administrated at ischemic reperfusion, cardiac tissue was isolated and 
homogenised, followed by protein detection using SDS-PAGE and Western Blotting.                                                     
Results: Administration of insulin, the GSK3β-inhibitor SB-415286 or the combination of the two, 
for 15 minutes from the onset of ischemic reperfusion, significantly reduced infarct size in the 
isolated ex vivo female rat heart as compared to control (Ins 29.9±5.5%, GSK3β-inh 29.4±2.7%, 
Ins+GSK3β-inh 27.1±5% vs. control 45.9±3.0%). No synergistic cardioprotective effect was 
observed with the combinational treatment, and also no difference in the response of female and male 
rat hearts was observed. Preliminary data suggest that phosphorylation of the prosurvival kinase Akt 
is involved in insulin mediated cardioprotection. However, its phosphorylation status is not affected 
by treatment with GSK3β-inhibitor.                                                                                              
Conclusion: Insulin, the GSK3β-inhibitor SB-415286 and insulin+GSK3β-inhibitor confers 
cardioprotection in terms of reducing infarct size in the isolated ex vivo female rat heart, when 
administrated for 15 minutes at the immediate onset of reperfusion. Our preliminary data suggests 
that the prosurvival kinase Akt is involved in insulin treatment administered at reperfusion.   
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1. Introduction 
1.1 Background 
Cardiovascular disease is the major cause of death worldwide, and is responsible for nearly 
40% of the mortality in Europe before the age of 74 [1]. In Norway, 35% of all deaths in 
2006 was a consequence of this diseased state, and of these approximately 40% were caused 
by ischemic heart diseases such as myocardial infarction, angina pectoris and arteriosclerosis 
[2]. Myocardial ischemia is caused by a coronary occlusion leading to reduced blood flow to 
the affected part of the heart, with increased risk of acute myocardial infarction (AMI) and 
irreversible tissue damage. In most cases, the occlusion is caused by a disruption in the 
vascular endothelium associated with unstable arteriosclerotic plaque. If the blood supply to 
the heart becomes too low to ensure adequate oxygen levels, the maintenance of normal 
oxidative metabolism will be impaired, leading to what is defined as an ischemic condition 
[3]. To reduce severe damage of ischemic myocardium, rapid restoration of coronary blood 
flow (reperfusion) is essential. In the clinic, this is normally achieved by the use of 
thrombolytic therapy, coronary artery bypass graft surgery, or primary percutaneous 
coronary intervention (PCI). Paradoxically, the reperfusion phase can simultaneously lead to 
increased cell death and myocardial damage, a phenomenon termed reperfusion induced 
injury. 
Data from Statistics Norway (Statistisk Sentralbyrå) state that 48% of all deaths caused by 
ischemic heart disease in Norway are among women [2] ; however the majority of all cardiac 
research is performed on the male specie. Previous studies also show differences between 
genders in the response to myocardial ischemia, with premenopausal women appearing to be 
better protected [4-6]. To further investigate these findings, the main objective of this project 
was to explore whether pharmacological treatments with insulin, GKS3β- inhibitor and a 
combination of the two, could reduce the extent of reperfusion induced injury caused by 
AMI in the ex vivo female rat heart. Parallel experiments on male rats were performed by a 
colleague (Anita Wergeland), to investigate a potential sex-difference in the response of the 
various treatments.     
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1.2 Myocardial ischemia 
Myocardial ischemia is defined as inadequate oxygen supply to myocardial tissue caused by 
a reduction in coronary blood flow. The two main consequences of ischemia are: A) lack of 
adequate amounts of oxygen and nutrients and B) reduced washout of metabolites such as 
lactate, protons, NADH2 and CO2 [7] (Fig.1-1).   
The reduced amount of oxygen available to the mitochondria of the ischemic cells, inhibit 
their capacity to aerobically metabolize fatty acids (Fig. 1-1A). Consequently, a rapid 
decline in ATP will occur, which again will stimulate cells to initiate glycolysis, resulting in 
increased levels of lactate and protons (the latter from breakdown of ATP). This increase, 
together with accumulation of other metabolic waste products due to reduced washout, will 
inhibit glycolysis and further reduce the levels of ATP.  
 
 
 
 
 
 
 
 
 
Figure 1-1: The main consequences of ischemia:  (A): Reduced O2 delivery and (B) poor wash out of various 
metabolites are the major consequences of ischemia. A decrease in oxygen supply will down regulate oxidation 
of fatty acids and reduce the production of ATP. Accumulation of lactate, protons and CO2 will occur due to 
reduced wash out, leading to cellular acidosis and proteolysis. Depletion of ATP will inhibit ATP dependent 
ion pumps resulting in potassium loss, water retention and cell swelling. As for the increase in lactate and 
proton levels, the glycolysis will be inhibited, causing a rise in Ca2+-levels and damage of the mitochondria. 
The ischemic cascade culminates in cell death either by necrosis or apoptosis. (Figure modified from Opie 
2004 [3]) 
ISCHEMIA
Reduced O2 
delivery Reduced washout
Fall in ATP Fatty acid metabolism ↓
Inhibition of ion
pumps
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Due to insufficient ATP levels, the contractile force of the myocardial cells will decrease 
markedly [8]. In addition, ATP-dependent ion pumps will be inhibited, leading to an ionic 
imbalance in the cell [7] (Fig. 1-1A). Potential consequences are damage of contractile 
proteins, activation of phospholipases, increased depolarization, ischemic contracture and 
mitochondrial damage [3]. Accumulation of lactate, protons and CO2 will give rise to an 
acidic environment in the cell, which again will promote proteolysis and cell death [3] 
(Fig.1-1B).  
It is important to address the metabolic differences between mild and severe ischemia. In a 
normal oxygenated heart, oxidation of fatty acids is the main source of energy and high 
levels of ATP and citrate will in this case inhibit glycolysis in myocardial cells. If the heart 
is subjected to mild ischemia, the depletion of ATP will cause stimulation of glycolysis. In 
contrast, glycolysis will be inhibited during severe ischemia due to reduced glucose delivery 
to the heart, as well as accumulation of lactate and protons. These metabolic changes will 
reduce the ability of the tissue to survive [3]. 
The severity of an ischemia is also determined by the position of the occlusion. A complete 
restriction of blood flow to the heart caused by an occlusion in aorta is defined as global 
ischemia. In contrast, if the occlusion is situated in the coronary arteries, only supplying 
blood flow to a specific area of the cardiac tissue, the condition is termed regional ischemia. 
As previously mentioned, the contractile force decrease markedly in ischemic cells,  
however, if ischemia persists less than 15 minutes, the myocardial cells are able to restore 
electric and mechanical activation [8]. On the other hand, if the myocardium is subjected to 
a longer period of ischemia, some of the cells will die [8]. In this project, ex vivo isolated 
female rat hearts were subjected to 30 minutes of regional ischemia by occluding the left 
anterior descending coronary artery (LAD). 
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1.3 Myocardial reperfusion injury 
Reperfusion is defined as restoration of blood flow to a previous ischemic area, and is a 
necessary process to reduce tissue damage. Paradoxically, reperfusion can at the same time 
activate a cascade of reactions leading to increased myocardial damage [9], a phenomenon 
termed myocardial reperfusion injury. Jennings et al. [8] were the first to describe this, and 
later, four types of reperfusion injuries have been recognized: 1) myocardial stunning, 2)  
microvascular damage (reduced perfusion) 3) reperfusion arrhythmias and 4) lethal 
reperfusion injury [10]. Myocardial stunning refers to post-ischemic mechanical dysfunction 
despite restoration of normal blood flow and absence of irreversible damage [3, 9]. The 
condition is transient and the heart will normally recover fully within days or weeks. 
Microvascular damage is also a potential harm caused by reperfusion, and refers to 
impairment in blood delivery and hence reduced perfusion of some of the previous ischemic 
areas [11]. A third complication that can arise during reperfusion is arrhythmias. If left 
untreated, this is a lethal diseased state; however anti-arrhytmics are efficiently used to 
prevent this. Many researchers have investigated the three types of reperfusion damage 
described above, leaving lethal reperfusion injury as the more unexplored factor [10].  
1.3.1 Lethal reperfusion injury 
Lethal reperfusion injury is defined as death of myocardial cells caused by restoration of 
coronary blood flow after an ischemic event [10], e.g. after percutaneous coronary 
intervention (PCI) or in a surgical setting. An important point is that the affected myocardial 
cells are viable immediately before the reperfusion sets in, and consequently the possibility 
of rescuing these cells has received increased attention. Several studies have shown that 
administration of pharmacological agents at the immediate onset of reperfusion will reduce 
the extent of cell death after an ischemic episode [12-17], supporting the concept of lethal 
reperfusion injury as an important contributor to the total myocardial damage caused by an 
ischemic event. For patients suffering from AMI, this could therefore be a great step forward 
in developing new therapeutic strategies, aiming to salvage the reperfused myocardium. 
The mechanism leading to lethal reperfusion injury still remains incomplete, however 
several cellular events are described in the literature as possible theories: A) oxidative stress,           
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B) Calcium (Ca2+) overload, C) restoration of physiologic pH and D) opening of the 
mitochondrial permeability transition pore (mPTP) [10] (Fig. 1-2). There is good evidence of 
increased oxidative stress in the reperfused ischemic myocardium, which itself can cause 
myocardial injury [18]. As presented in Figure 1-1, cell swelling followed by membrane and 
mitochondrial damage is a consequence of ischemia, and this can amplify during the 
reperfusion phase. The increased formation of oxygen-derived free radicals has shown to be 
an important factor leading to increased cellular damage and cell death. These highly 
reactive molecules have shown to combine with polyunsaturated fatty acids to form lipid 
peroxides and hydroperoxides, which in turn can inhibit enzymes, damage the sarcolemma 
and mitochondrial membrane, impair cellular calcium transport,  and thereby cause further 
cellular damage [9]. 
 
 
 
 
 
 
 
 
 
 
Figure 1-2: The main events of lethal reperfusion injury:  During myocardial reperfusion an abrupt increase 
of Ca2+ (B, green) together with increased production of reactive oxygen species (A, yellow) and pH 
restoration (C, blue) interact to mediate increased cardiomyocyte death. The opening of the mPTP- channel (D) 
is mainly responsible for this by uncoupling oxidative phosphorylation and inducing mitochondrial swelling 
with the release of pro- apoptotic factors, (Figure modified from Yellon, 2008 [10] ).  
 
A)
B)
C)
D)
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In addition to oxidative stress, an abrupt increase in Ca2+ concentration in the reperfusion 
phase has shown to be one of the main contributors to lethal reperfusion damage [10, 19]. 
Production of free radicals, activation of phospholipases with damage of the sarcolemma and 
mitochondrial membrane are consequences of this change, which again is associated with 
increased contracture, cell swelling and necrosis [9]. 
At the onset of reperfusion, the washout of metabolites in the heart, including lactate, 
gradually increases. Hence, the acidic environment arising during ischemia will restore to 
physiologic pH (~7.4). Activation of the sodium-hydrogen exchanger and the sodium- 
bicarbonate symporter will also contribute to this. Paradoxically, studies have shown that the 
return from acidic to normal pH after reperfusion accelerates cell death, thereby becoming 
another cause of lethal reperfusion injury [20]. 
As illustrated in Figure 1-2, the described oxidative stress, Ca2+ overload and pH correction 
arising in the reperfusion phase, all mediate opening of the mitochondrial permeability 
transition pore (mPTP), which are non-selective channels situated in the inner mitochondrial 
membrane. Opening of this pore leads to influx of solutes and water followed by swelling of 
the mitochondrial matrix. Subsequently, the outer mitochondrial membrane will burst, 
leaking various pro-apoptotic substances into the cytosol that will initiate apoptosis [21]. As 
expected, several studies have shown that inhibition of this mPTP- channel have a 
cardioprotective effect in reducing the extent of lethal reperfusion injury [21-23], from now 
on termed reperfusion injury. 
1.3.2 Apoptosis versus necrosis 
It is widely accepted that prolonged severe myocardial ischemia leads to cell death; 
however, the type of cell death contributing to this has been under intense investigation for 
many years. Today results are indicating that both necrosis and apoptosis are involved in 
myocardial ischemic- and reperfusion induced cell death. Necrosis is defined as cell death, 
most commonly caused by swelling of the cell and its organelles [24]. The cell will 
eventually burst (lysis) leading to the release of intracellular components, that will attract 
macrophages, activate fibroblast and hence give an inflammatory response (Fig. 1-3A). 
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Apoptosis is defined as a genetically programmed event, leading to cell shrinkage and 
degeneration of intracellular components without any rupture of the cell membrane [25]. The 
mitochondria remain intact in this process, whereas the nucleus is broken down, followed by 
cleavage of the DNA. When the cell shrinks, fragments are released in form of apoptotic 
bodies, which again are phagocytised by neighbouring cells (Fig. 1-3B). As distinct from 
necrosis, apoptosis do not result in any fibrosis, inflammation or scar formation [25]. 
Until recently, it was suggested that necrosis was the main event leading to ischemia- 
reperfusion induced injury. However, more recent studies also support apoptosis as an 
important contributor to this damaging process [26, 27]. As apoptosis is genomically 
regulated and can be manipulated, there has been an increased focus on the reperfusion 
phase as a target for cardioprotection both through pharmacological interventions and 
intentional variation of perfusion conditions (pre- and post-conditioning). Substantial  
research have been performed [12-17, 28, 29], but none of the experimental strategies have 
yet been routinely established in clinical practice [30]. 
 
 
 
 
 
 
 
 
 
Figure 1-3: Necrosis versus apoptosis: Two types of cell death are involved in myocardial ischemic- 
reperfusion injury. A) Necrosis leads to rupture of the cell membrane, release of intracellular components and 
finally inflammatory reactions. B) Apoptosis is a more organized process with cell shrinkage and formation of 
apoptotic bodies which are phagocytised by surrounding cells (Figure modified from Opie, 2004 [25] ).   
A) B)
INFLAMMATION PHAGOCYTOSIS
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1.3.3 Reperfusion therapy 
As already mentioned, early reperfusion is important to limit the injury after an ischemic 
episode. Simultaneously, suppression of the cell death caused by reperfusion itself would be 
favourable to improve patient outcome. This is one of the main limitations of the reperfusion 
therapy used in the clinic today, as they do not influence the signalling pathways leading to 
increased cell death in the reperfusion phase. More recent approaches include pre- and post- 
conditioning where the heart is subjected to one or more episodes of sub-lethal ischemia 
followed by reperfusion, either prior (pre) or after (post) the main ischemic event. Both these 
techniques have shown to be powerful protectors against ischemic reperfusion injury by 
activating the reperfusion injury salvage kinase (RISK) cellular pathway [28, 29]. This 
pathway mainly activates two key proteins, namely Akt and Erk1/2 which both are known as 
prosurvival kinases [28]. Subsequently, the recruitment of the RISK pathway, for instance 
through pharmacological interventions, allow one to benefit from the cardioprotective 
effects seen in both pre- and post- conditioning. 
1.3.3.1 Insulin therapy 
One example of a pharmacological intervention used as reperfusion therapy is insulin 
administration. Insulin is a polypeptide hormone with extensive biological effects including 
regulations of glucose metabolism, protein and lipid synthesis, as well as gene transcription 
[31]. The biological effects are exerted by its binding to the α subunit of the heterodimeric 
insulin receptor situated in the cell membrane. Further on, the intrinsic tyrosine kinase 
activity of the α subunit induces phosphorylation of the β subunit of the receptor, leading to 
activation of various signalling pathways. Amongst these are the prosurvival 
phosphatidylinositol 3- kinase (PI3K) – Akt/ protein kinase B (PKB) signalling pathway, 
which is responsible for most of the metabolic actions of insulin [32]. Interestingly, this has 
also shown to be one of the main routes in the RISK signalling pathway [28]. As illustrated 
in Figure 1-4, phosphorylated Akt results in subsequent phosphorylation of various proteins, 
including p70 S6 kinase, mTOR and BAD. The overall effect of these cellular events is 
inhibition of apoptosis with increased cell survival [14]. 
The role of insulin as a promoter for cell survival, in the context of reperfusion injury, is 
investigated in several studies [14, 27]. Jonassen et al. showed that insulin administrated for 
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the first 15 minutes of reperfusion, significantly reduced infarct size in the isolated perfused 
male rat heart by activating the PI3K/Akt cell surviving signalling cascade [14]. In addition, 
the cytoprotective effect of insulin at reoxygenation were demonstrated to attenuate 
apoptosis in rat neonatal cardiomyocytes [27]. More recent studies by Tsang et al. describes 
a correlation between activation of the PI3K/Akt pathway and inhibition of mPTP opening 
[29], giving rise to a possible explanation of insulin’s cardioprotective effect. As previously 
described, several factors (Ca2+, ROS, pH) mediate opening of the mPTP during 
ischemia/reperfusion, however, insulin’s direct effect on these factors are not yet fully 
understood. Still, opening of the mPTP have shown to induce the release of pro- apoptotic 
factors, and hence contribute to increased cardiomyocyte death. Together, this demonstrates 
the possibility to modify pro- apoptotic cellular pathways with pharmacological agents, such 
as insulin, in order to reduce to extent of reperfusion injury. 
 
Figure 1-4: Insulin signalling: Insulin (INS) binds its tyrosine kinase receptor (RTK) in the cell membrane 
which then gets phosphorylated. This initiates the phosphorylation, and hence activation, of PI3-kinase and 
Akt with the following phosphorylation of various intracellular proteins; mTOR, p70S6 Kinase and BAD. The 
net effect of this signalling cascade is inhibition of pro- apoptotic pathways and increased cell survival (Figure 
modified from Jonassen, 2002 [33]) 
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1.4 Glycogen Synthase Kinase 3β (GSK3β) 
The present study focuses on a pathway for insulin mediated cell survival, compromising the 
multifunctional enzyme Glycogen synthase kinase 3 (GSK3).  The name of the enzyme came 
from its ability to phosphorylate and thereby inactivate glycogen synthase, which is an 
important enzyme in the process of glycogen synthesis. There are two homologous isoforms 
of this enzyme, namely GSK3α and GSK3β, both exerting catalytic activity towards a 
number of intracellular substrates [22]. The two isoforms have 98% identity in their central 
catalytic domain [34], however the β isoform is reported to have a generally higher catalytic 
activity than the α isoform [35]. Moreover, studies with mice demonstrate that deletion of 
the GSK3β gene cause developmental arrest and embryonic lethality, thus indicating that 
GSK3α is unable to compensate for this gene loss [36]. Hence, GSK3β has been recognized 
as the most important isoform of the GSK3 enzyme. 
GSK3β is a ubiquitously expressed and constitutively active enzyme, with the ability to  
phosphorylate and hence, regulate various cellular functions, including development, 
metabolism, gene transcription, protein translation, cell cycle and apoptosis [37]. As GSK3β 
is known to negatively regulate downstream signalling pathways, inhibition of this enzyme 
will stimulate these pathways, by removing the negative constrain imposed by GSK3β [38]. 
The active enzyme is described to facilitate apoptosis [39], a correlation that has been widely 
studied over the last years. An identified key mechanism is the ability for GSK3β to 
downregulate various transcriptional factors important for cell survival processes [37]. 
Additionally, GSK3β facilitates opening of the mPTP, resulting in the release of various pro- 
apoptotic factors from the mitochondria [22, 40]. 
1.4.1 GSK3β regulation 
Various factors regulate GSK3β activity, including stimulatory tyrosine phosphorylation, 
formation of protein complexes and intracellular location. However, inhibition of the 
constitutively active enzyme through phosphorylation of the Ser-9 site has shown to be the 
most essential regulation mechanism in terms of anti-apoptotic actions (Fig. 1-5) [37]. 
Sutherland et al. were the first to identify GSK3β phosphorylation and showed this through 
in vitro phosphorylation of the enzyme both by MAPKAP kinase-1 (also called p90Rsk) and 
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p70S6 kinase [41]. A more recent study in cardiomyocytes describes even more pathways 
leading to inhibition of GSK3β, including activation of PI3K/Akt- , PKC- and PKA 
pathways [22]. To summarize, the literature describes numerous pathways all converging in 
the phosphorylation and hence inhibition of GSK3β (Fig. 1-5).  
 
 
 
 
 
 
 
 
Figure 1-5: Regulation of GSK3β: Many upstream signalling kinases such as mTOR/p70s6K, protein kinase 
C (PKC), phosphatidylinositol 3- kinase (PI3K) / Akt, protein kinase A (PKA) and MAPK/MAPKAP-K1 are 
reported as inhibitors of GSK3β through phosphorylation at Ser-9. Based on Juhaszova et al., 2004 [22].  
 
1.4.2 GSK3β and cardioprotection 
Several studies describe that inhibition of the constitutively active GSK3β through 
phosphorylation, leads to cardioprotection. Pre- and post-conditioning as described earlier 
[28], administration of opioids [42], erythropoietin [43] and propofol [44] are all treatments 
that have shown to be cardioprotective by increasing GSK3β phosphorylation. However, the 
so far most comprehensive study of GKS3β and cardioprotection, is the one performed by 
Juhaszova and colleagues [22]. Their data show a wide variety of drugs, including insulin, 
diazoxide and an N+-H+ exchanger inhibitor, exerting a protective effect in cardiomyocytes 
through increased phosphorylation of Ser-9 and thus inactivation of GSK3β with the 
following reduction in mPTP- opening and apoptosis. To verify these findings, additional 
PI3K/Akt
mTOR/p70s6K MAPK/MAPKAP-K1
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studies were performed on transgenic mice with a serine-9-to-alanine mutation, and hence a 
signal- resistant GSK3β enzyme. When treated with the same drugs as described above, no 
cardioprotection was observed. These results further prove the important role of GSK3β 
inhibition in the cell survival pathways facilitating cardioprotection [22]. 
Consistent with the findings of Juhaszova et al., more recent studies by Gross et al. 
demonstrate that administration of the selective GSK3β – inhibitors SB-216763 or SB-
415286 either 5 minutes before the onset of reperfusion or 10 minutes before the ischemic 
event, significantly reduced infarct size in the in vivo rat heart [23, 42]. Additional 
experiments also show that co-treatment with both SB-216763 and inhibitors of  the 
PI3K/Akt and mTOR signalling cascade reduce infarct size in the in vivo rat heart, indicating 
that Akt and mTOR are upstream negative regulators of GSK3β (Fig. 1-5) and that SB-
216763 is a direct inhibitor of GSK3β working independently of these pathways [42]. 
Based on the literature described, and the research interest of our group, this project was 
initiated to further investigate the involvement of GSK3β inhibition and insulin in 
cardioprotective reperfusion therapy in the female heart. As myocardial infarction is a 
sudden, acute condition, pharmacological treatment before the onset of ischemia is difficult. 
In contrast, drug administration in the reperfusion phase, which is when the occluded artery 
is mechanically or pharmacologically reopened, would be a more applicable approach. With 
the clinical aspect in mind and in contrast to the work done by Gross et al. [23, 42], we have 
administered drugs at the onset of reperfusion instead of prior or during the ischemic phase. 
More specifically, we wanted to investigate whether the GSK3β- inhibitor SB-415286 
administrated for 15 minutes from the onset of reperfusion, offers cardioprotection after an 
ischemic event. Additionally, as insulin has been shown to phosphorylate GSK3β via the 
PI3K/Akt pathway, we wanted to explore whether combinational treatment of insulin and 
the GSK3β-inhibitor had any synergistic cardioprotective effect. An overview of the cellular 
pathways involved in this treatment is illustrated in Figure 1-6.   
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Figure 1-6: Insulin and GSK3β- inhibitor therapy: Insulin is a known activator of the PI3K/Akt pathway 
which leads to phosphorylation (P on Ser-9) and inhibition of GSK3β. SB- 415286 acts as a potent inhibitor of 
GSK3β by binding an important ATP site on the enzyme. The cardioprotective effect observed with GSK3β 
inhibition can be explained by reduced mPTP opening, less apoptosis and hence increased cell survival. By 
inhibiting the enzyme using both insulin and SB-415286, we hypothesise a synergistic cardioprotective effect.   
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1.5 Aims of study 
The specific aims of this study are:  
1) Explore if insulin therapy administrated at ischemic reperfusion also confer 
cardioprotection in the isolated ex vivo female rat heart.  
2) Identify whether the GSK3β-inhibitor SB-415286 administrated for 15 
minutes from the onset of reperfusion can reduce infarct size in the isolated ex 
vivo female rat heart.  
3) Delineate whether there is a synergistic effect by combining insulin and 
GSK3β-inhibition (SB-415286) treatment at reperfusion in terms of reducing 
infarct size.  
4) Investigate the phosphorylation status of Akt at early ischemic reperfusion in 
the isolated ex vivo female rat heart, after being exposed to the various 
treatments described above.  
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2. Materials and methods 
Three distinct methods have been used in this project; perfusion of ex vivo isolated rat hearts 
in the Langendorff setup, isolation of heart tissue and finally Western Blotting. To evaluate 
the cardioprotective effect of our treatments, ex vivo isolated rat hearts were perfused 
through the Langendorff system, subjected to regional ischemia, treated with various agents 
at reperfusion and finally examined for determination of infarct size. Isolation and 
homogenisation of cardiac tissue, followed by protein detection with SDS- PAGE and 
Western Blotting was performed to investigate the role of the prosurvival kinase Akt in the 
various treatments.  
2.1 The isolated ex vivo Langendorff perfused rat heart 
2.1.1 Animal preparation 
Female Wistar rats ordered from The Norwegian Institute of Public Health were used in the 
experiments (200 – 300 g, n=37). They were kept in the Animal Department at the Institute 
for Biomedicine, University of Bergen and were fed a standard diet with free access to 
water. All experiments were approved by the Norwegian State Commission for Laboratory 
Animals (id#1265 in “Forsøksdyrutvalgets tilsyns- og søknadssystem”, FOTS), and carried 
out in accordance with the European Communities Council Directive of 1986 (86/609/EEC). 
The rats were anesthetized with Pentobarbital 50mg/kg (i.p.) and simultaneously given 
200IE (0.01mL) of the anticoagulant Heparin (Leo Pharma A/S). Before heart excision, both 
pedal and palpebral reflexes were checked to confirm adequate sedation. 
2.1.2 Langendorff perfusion setup 
Isolated female rat hearts were cannulated by the aorta and perfused through the 
Langendorff perfusion setup, allowing us to study heart function ex vivo (Fig. 2-1). Two 
separated reservoirs placed above the perfusion cannula were heated (37°C), oxygenated 
(95% O2, 5% CO2) and filled with Krebs- Henseleit buffer (KHB) (see Appendix) with or 
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without supplementation of the various treatment agents. Before the perfusion fluid entered 
the reservoirs, it was filtered through a 5.0 μM Millipore filter to ensure a fluid free from 
particles. By placing the reservoirs 1 meter above the heart, a constant hydrostatic pressure 
of 80 mmHg was maintained as long as the reservoirs were filled up to a marked level.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-1: The Langendorff constant pressure isolated heart perfusion system. Two reservoirs connected to 
a perfusion cannula, ensured retrograde perfusion of the heart through aorta at a constant hydrostatic pressure 
(80 mmHg). One reservoir was filled with oxygenated Krebs-Henseleit buffer (KHB; left) while the other 
reservoir was filled with an oxygenated solution of drug (right). The side arm on the perfusion cannula allowed 
us to inject a solution of a second drug simultaneously, using a syringe pump. A temperature of 37 °C was 
maintained as the reservoir was surrounded by warm circulating water. To measure hemodynamic parameters 
such as heart rate and left ventricular developed pressure (LVDP), a water filled balloon was inserted into the 
left ventricle and connected to a pressure transducer coupled to a Power Lab recorder and a computer. The 
coronary flow could also be determined by timed measurements of the coronary effluent. (Figure modified 
from Sutherland et al., 2000 [45]). 
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Perfusion fluid was led from the reservoirs, via rubber tubes and into a “bubble trap” with 
the function of removing/trapping air bubbles generated in the system. Further, the fluid was 
led through another tube and finally transferred via the cannulated aorta and into the heart. 
The perfusion cannula also contained a side arm, where administration of a second solution 
of drug could be performed using a syringe pump. A volume equivalent to 1/10 of the hearts 
coronary flow was introduced to the heart per minute, and by preparing a 10x concentration 
of the drug solution, the right dosage was ensured through the syringe pump. To monitor 
heart function, a small water filled latex-balloon connected to a pressure transducer 
(Edwards Lifescience LLC, CA, USA) was inserted into the left ventricle, hence giving 
measurements of both heart rate (HR) and left ventricular developed pressure (LVDP; 
LVDP= SP (Systolic pressure)  – DP (Diastolic pressure)). The pressure transducer was 
calibrated with two known pressures (0 and 200 mmHg) before every experiment to ensure 
comparable measurements (see Appendix B for detailed description). 
 
2.1.3 Langendorff perfusion procedure 
Anesthetized rats were subjected to transabdominal incision and thorax was opened by 
cutting the ribs adjacent to sternum. The heart and a part of aorta were detached and 
transferred to ice-cold Krebs-Henseleit buffer (KHB), before being mounted onto the 
Langendorff perfusion system within 1 minute after excision (Fig. 2-1). This was performed 
by gently easing the aorta over the cannula, using a “bulldog” clamp to temporarily attach 
the heart, before tying a permanent silk suture around the aorta. Perfusion through the aorta 
was initiated and the heart was retrogradely perfused with oxygenated Krebs-Henseleit 
buffer (KHB). A constant hydrostatic pressure of 80mmHg ensured closure of the aortic 
valves and the heart was thereby perfused via the coronary ostia and drained into the right 
atrium through the coronary sinus [45].  
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Once the heart was adequately cannulated and subjected to perfusion buffer, normal heart 
rhythm and contractile function would re-establish within short time (seconds). A 3.0 silk 
suture attached to a small curved needle was then introduced to the heart and passed around 
the main branch of the left anterior descending artery (LAD; Fig. 2-3). The two ends of the 
suture were passed through a small plastic pipette tip to form a snare. By carefully tightening 
the suture, regional ischemia was introduced (Fig. 2-4), while reperfusion was achieved by 
releasing the snare. 
 
Figure 2-3: The isolated rat heart: The heart was cannulated via aorta and retrogradely perfused with KHB- 
buffer. To be able to induce regional ischemia, a silk suture attached to a curved needle was passed around the 
main branch of the left anterior descending artery (LAD).      
 
To monitor cardiac function, a small pointed scissor was used to make a small opening in the 
left atrium in which a small compliant balloon of elastic rubber was inserted, passed through 
the mitral valve and placed into the left ventricle (Fig. 2-4). The balloon was connected via a 
water filled plastic catheter to a hydrostatic pressure transducer which was coupled to a 
Power Lab recorder (Power Lab System, AD Instruments). A microsyringe was used to fill 
the balloon with water until a left ventricular end diastolic pressure of 5-10 mmHg was 
obtained. In addition to left ventricular pressure measurements (diastolic, systolic and 
developed pressure) the balloon provided information about heart rate. All the mentioned 
data were recorded by the Power Lab and graphically expressed on the computerized 
program Chart-5 (AD Instruments) (Fig. 2-5). 
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Figure 2-4: The isolated rat heart during regional ischemia. A) To measure left ventricular pressure, a water 
filled latex balloon connected via a water filled catheter to a pressure transducer, was inserted into the left 
ventricle. B) A silk suture was passed around the left anterior descending artery (LAD) and C) two plastic 
pipettes were used to form a snare. By tightening the suture, regional ischemia was introduced, and reperfusion 
was achieved by releasing it. 
 
 
      
 
 
 
 
 
Figure 2-5: Data collection using the Power Lab. The graph demonstrates recordings of the left ventricular 
systolic and diastolic pressure (mmHg) during the stabilisation period. Peaks indicate the systolic pressure (SP) 
while the lowest points indicate diastolic pressure (DP). Left ventricular developed pressure (LVDP) is 
determined as: LVDP= SP-DP. The heart rate (HR) expressed in beats per minute is calculated by counting a 
minimum of 20 peaks (heartbeats) of the pressure curve and adjusting it in relation to time.    
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Temperature of 37- 37.5 °C was maintained by placing a water circulated heat chamber 
made of glass around the isolated heart, and was monitored by inserting a small thermistor-
probe into the pulmonary artery. A measuring cylinder was placed below this chamber 
where coronary effluent was collected, thus, the heart’s coronary flow (CF) measured in 
millilitres per minute could be determined (Fig. 2-1). 
 
2.1.4 Measurement of infarct size 
At the end of the experimental protocol, measurements of infarct size and risk zone were 
carried out as described by Ytrehus et al. [46]. The silk suture, used to induce regional 
ischemia, was again securely tightened around the left coronary artery (LAD), followed by 
injection of Evans blue dye (0.2 % w/v) through the sidearm of the cannula. This last step 
ensured demarcation of the area subjected to ischemia (area at risk of infarction = non- 
stained by Evans Blue) and the non-ischemic part of the heart (stained by Evans Blue) (Fig. 
2-6). 
 
Figure 2-6: Determination of area at risk by injection of Evans Blue. The silk suture used to induce regional 
ischemia was re-tightened followed by injection of 2 ml of Evans Blue (0.2% w/v) via the sidearm of the 
cannula. Hence, only the area that had not been subjected to ischemia was perfused with the blue dye, whereas 
the ischemic area (area at risk) remained unstained. 
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Hearts were thereafter weighed, frozen and partly thawed, before being cut into 2 mm thick 
slices from the apex to the atrioventricular groove. Thawed heart slices were incubated in 
1% triphenyl- tetrazolium- chloride (TTC; Sigma- Aldrich) solved in phosphate buffer (pH= 
7.4, Appendix A) at 37°C for 20 minutes to ensured staining of the viable part of the risk 
zone (Fig. 2-7). A deep red colour develops as TTC reacts with NADH and dehydrogenase 
enzymes present in viable cells. Finally, the slices were immersed in 10% Formalin 
(Appendix A) in 1-3 days to enhance the contrast of stain between viable and non-viable 
areas (Fig. 2-7). 
 
 
Figure 2-7: Triphenyl- tetrazolium- chloride (TTC) staining: The hearts were cut into 2mm thick slices and 
stained with 1% TTC to separate viable from dead tissue. TTC staining was performed at 37°C for 20 minutes, 
followed by 1-3 days in formalin. A) The dark blue tissue represents the Evans blue staining, hence the area 
not subjected to ischemia. B) The red tissue marks the viable part of the ischemic area, while C) the white/grey 
tissue represents non-viable tissue. 
 
Two glass plates separated by a 2 mm spacer ensured compression of the heart slices to a 
uniform thickness, and the slices were scanned (Epson Perfection 4490 Photo) to further 
analyze our result. Determination of the infarcted area (tetrazolium negative, grey), the 
viable risk zone (tetrazolium positive, red) and the area not subjected to ischemia (blue) was 
performed using the computerized programme Planimetry+ (Traasdahl, University of 
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Tromsø, Norway). Tracing of the various areas with a digitalized tracing pad (Acedad III, 
Graphics Tablet) allowed us to analyse pixel density (Fig. 2-8). Hence, heart-volume, 
infarcted-volume and risk zone-volume, all expressed in mm3, could be calculated by 
multiplying each area (mm2) with the slice thickness (2mm) and then summing the products 
of each slice. The size of the infarction could then be expressed as a percentage of the area at 
risk (infarct/risk ratio (%)). 
 
 
 
 
Figure 2-8: Example of digitalized tracing analysis using Planimetry+: The different areas of the heart were 
traced using a digitalized tracing pad. Separation of the areas was done by using different colour codes: Red = 
non-viable area, green = viable part of the area at risk, yellow = area not at risk. A pixel density analysis 
calibrated to represent mm3, was then performed to calculate the % infarct area/ area at risk ratio. A) Control 
heart perfused with KHB B) Heart co-treated with insulin and GSK3β-inhibitor. 
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2.1.5 Experimental protocol 
The experimental protocol is shown in Figure 2-9. All hearts were stabilized for 20 minutes 
before being subjected to 30 minutes of regional ischemia (RI) and 120 minutes of 
reperfusion. Four groups of isolated hearts were studied: 1) Control (n=13), 2) Insulin (0.3 
mU/mL, n=7), 3) GSK3β- inhibitor (3μM, n=8) and 4) Insulin + GSK3β- inhibitor (n=9). 
The control group was perfused with Krebs Henseleit Buffer (KHB) throughout the 
experiment, while the three following groups were respectively treated with Insulin (Novo 
Nordisk A/S, Denmark), the GSK3β- inhibitor SB-415286 (Tocris Bioscience, UK) or the 
combination of insulin and the GSK3β- inhibitor for 15 minutes given at the onset of 
reperfusion (Fig. 2-9). 
 
 
 
 
 
 
 
 
 
 
Figure 2-9: Experimental protocol for the isolated rat hearts subjected to regional ischemia and 
reperfusion. All hearts were stabilized for 20 minutes prior to 30 minutes of regional ischemia (RI) and 120 
minutes of reperfusion. The control group was administrated Krebs-Henseleit buffer (KHB; dotted lines) 
throughout the entire protocol (for 170 minutes), while the three other groups received a 15 minutes treatment 
of either insulin (blue line), GSK3β- inhibitor (red line) or a combination of the two (turquoise line), from the 
onset of reperfusion.  
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2.2 Immunoblotting 
To investigate which intracellular pathways insulin and the GSK3β inhibitor activate when 
administrated at ischemic-reperfusion, cardiac tissue was isolated and homogenised, 
followed by protein detection with SDS- PAGE and Western Blotting.  
2.2.1 Tissue isolation 
Hearts (n=25) were mounted onto the Langendorff perfusion setup and underwent protocols 
as presented in Figure 2-10. Baseline groups were subjected to a stabilisation period of 20 
minutes, perfused with either KHB (ControlBL), 0.3mU/mL insulin (InsulinBL) or 3μM 
GSK3β- inhibitor (GSK3β-inhBL). The other hearts went through the ischemia-reperfusion 
period; however, the collection of tissue was performed after 15 minutes of reperfusion and 
injection of Evans Blue dye (Fig. 2-10). Hearts were immediately put on ice followed by 
removal of the right ventricle. The left ventricle of the baseline hearts were cut into small 
pieces, while hearts being exposed to regional ischemia, were divided based on stained (area 
non at risk = Evans Blue positive) and non-stained (area at risk) areas. The tissue samples 
were snap frozen in liquid N2, and then stored at -80°C.  
 
 
 
 
 
 
 
 
 
 
 Materials and methods 
 31
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-10: Protocol for tissue isolation using the Langendorff perfusion setup: Baseline (BL) hearts were 
perfused with either Krebs Henseleit buffer (ControlBL; dotted line), 0.3 mU/mL insulin (InsulinBL; blue line) 
or          3 μM GSK3β-inhibitor (GSK3β-inhBL; red line) and collected after 20 minutes. 4 other groups 
underwent 20 minutes of stabilisation, followed by 30 minutes of regional ischemia (RI). At the onset of 
reperfusion the different groups were respectively perfused with KHB (ControlRep), insulin (InsulinRep), GSK3β 
inhibitor (GSK3β-inhRep) or the combination of the two (Insulin + GSK3β- inhRep, turquoise line) for 15 
minutes, before the tissue isolation was performed.  
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2.2.2 Tissue homogenisation and protein estimation 
Cardiac ventricular heart tissue was homogenised in lysis buffer (Appendix A) using the 
automated tissue homogeniser Precellys 24 (Bertin Technologies), programmed to 3x15 
seconds with 10 seconds break in between. Samples were then centrifuged (4°C, 14000 rpm, 
10 min) to remove cell debris, leaving a supernatant containing the cytosolic fraction. 
Protein concentration of this fraction was determined as described in the applied BCA 
Protein Assay Kit (Thermo Scientific), and by measuring absorbance of the samples using a 
microplate spectrophotometer (VERSAmaxTM). Samples of known protein concentrations 
and their correspondent absorbance were expressed in a standardcurve (Fig. 2-11), and the 
unknown concentration of our samples could then be determined by extrapolation on this 
curve. Based on the estimated protein concentrations, the amount of sample (μL) loaded onto 
the gel could be calculated, to ensure equal amounts of proteins (μg) in each lane. Before 
final storage at -20°C, the homogenised samples were mixed with Sample buffer (Bio-Rad) 
in ratio 3:1.    
 
 
 
 
 
 
 
 
 
Figure 2-11: Standardcurve for determination of protein concentrations: 4 standard samples of known 
protein concentration (0.5, 1, 1.5, 2 mg/mL) were mixed with the protein reacting BCA followed by 
measurement of light intensity using a spectrophotometer. These known concentrations were plotted against 
optical density (OD) in a linear standardcurve (y = A + Bx). The unknown protein concentrations of our 
samples could then be determined by mixing them with the same BCA, measuring optical density and 
calculating the x (concentration) in the linear standard function.    
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2.2.3 SDS- PAGE and Western Blotting 
Myocardial phosphorylated Akt in the area at risk of infarction was determined by SDS-
PAGE and Western Blotting using antibodies against p-Akt 473 (Cell Signalling) and total-
Akt (Santa Cruz). 
One dimensional SDS-PAGE (Sodium dodecyl sulphate - polyacrylamide gel 
electrophoresis; 12.5%) was used to separate the proteins by size. Samples containing 
Sample Buffer were slowly de-frozen on ice followed by 5 minutes boiling at 90°C to 
denaturise all proteins. 40μg of sample protein was loaded onto the gel in parallel lanes to a 
protein standard marker (Precision Plus ProteinTM, Bio-Rad) containing 10 peptides of 
various sizes, thus, serving as reference to easier detect the size of our protein of interest. 
The electrophoresis was carried out in Running Buffer (Appendix A) at 95V for 15 minutes 
to completely stack the proteins in the gel, and then at 120V for approximately 1 hour. 
Proteins were then transferred from the gel to a methanol pre-activated HypobondTM- ECLTM 
PVDF Membrane (Amersham Bioscience), using a Bio-Rad Transblot “sandwich” immersed 
in Transfer Buffer (Appendix A). This process was performed at 100V for 1 hour with 
stirring and in a cold environment to prevent the gel from melting. Further, the membrane 
was activated in methanol a second time and air-dried, followed by incubation with 5% non-
fat dried milk (Marvel Dried Skimmed Milk) in Tris-Buffered Saline 0.1% Tween-20 (TBS-
T; Appendix A) for 2 hours. The milk proteins saturate the membrane and prevent unspecific 
binding of antibodies. TBS-T was used to wash the membrane (2x2 minutes by hand and 
2x10 minutes on an orbital shaker) followed by incubation of primary antibody (p-Akt 
1:500) over night at 4°C on an orbital shaker. The following day, the membrane was again 
washed with TBS-T, probed with the appropriate secondary antibody (1:10000; anti- rabbit 
against p-Akt) for 1 hour at room temperature and finally washed one last time. Secondary 
antibodies used in this experiment are conjugated to a horseradish peroxidase enzyme (HRP) 
with the ability to amplify signals and increase detectability of our protein. Addition of the 
chemiluminescent agent ECL Western Blotting Substrate (Pierce) to the membrane ensured 
an electrochemical reaction with the HRP bound 2° antibody, producing luminescence which 
is directly proportional to the amount of probed protein (Fig. 2-12). A highly advanced 
CCD- camera (The Bio-Rad Gel Doc XR) was used to capture the strength of this light 
emission, expressing it as a digital image of the western blot. The Bio-Rad Quantity One® 
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software could finally optimize and analyse the images by quantifying the relative amount of 
protein based on its optical density (densometric reading).     
 
 
 
 
 
 
 
 
Figure 2-12: Immunohistochemical reactions on the protein containing membrane: The membrane 
containing the protein of interest (A) is probed with a 1° antibody at 4°C over night. Incubation of a 
horseradish peroxidase (HRP) conjugated 2° antibody for 1 hour at room temperature, ensures binding to the 
1° antibody.  To detect the protein of interest, an electrochemiluminescent agent (ECL) is added, causing a 
light emitting reaction with the HRP enzyme, being directly proportional to the amount of protein A on the 
membrane. Based on the strength of this reaction, protein quantification can be performed.    
2.3 Statistical analysis 
Values are presented as mean ± standard error of mean (SEM). One way analysis of variance 
(ANOVA), followed by a Fisher’s post hoc test, was used to test for significant differences 
between and within groups (Minitab 15, Minitab Inc, USA). P≤0.05 was considered 
statistically significant. 
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3. Results 
3.1 The isolated ex vivo Langendorff perfused rat heart 
3.1.1 Heart and body weight 
To exclude variation, the body weight of the rats was measured, as well as heart weight after 
completed protocol and infusion of Evans Blue dye. No statistical significant difference was 
found in either rat weight (200-300g) or heart weight (1- 1.7g) between the experimental 
groups.  
3.1.2 Infarct Size 
Infarct size was determined as the ratio between the volume of the infarcted area and the 
volume of area at risk, expressed in percentage (Fig. 3-1). Treatments with insulin, GSK3β-
inhibitor or the combination of both for 15 minutes at the onset of reperfusion, reduced 
infarct size with respectively 35%, 36% and 41% as compared to control (Ctr = 45.9±3.0% 
vs. Insulin= 29.9±5.5%, GSK3β-inh.= 29.4±2.7%, Insulin+GSK3β-inh.= 27.1±5%, p<0.05 ). 
However, no significant difference was observed in infarct size when comparing the insulin-, 
GSK3β- inhibitor- and insulin + GSK3β inhibitor groups (Fig.3-1).       
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Figure 3-1: Infarct size expressed as percentage of area at risk: Infarct size is expressed as percentage of the 
area at risk of infarction. Treatment with either Insulin (blue, n=7), GSK3β- inhibitor (red, n=8) or the 
combination of the two (turquoise, n=9) for 15 minutes at the onset of reperfusion, significantly reduced infarct 
size as compared to control (black, n=13). All values are presented as mean ± SEM. * p<0.05.  
 
In order to evaluate variations in size of the areas at risk, volumes in the various groups were 
compared. There was no statistical differences in the volumes of the risk areas between the 
various experimental groups (control 2475±279 mm3, insulin 2311±356 mm3, GSK3β-inh 
1924±217 mm3, insulin + GSK3β-inh 1550±126 mm3, p<0.05). Volume of infarct size 
(mm3) versus volume of area at risk (mm3) is presented in Figure 3-2, and reflects that all 
treated hearts had a lower infarcted volume compared to control hearts, although being in the 
same range of volume of area at risk (~1000-3000mm3). This implies that the infarct 
reducing effect of the various drug treatments was not a consequence of variation in area at 
risk, but rather a result of the treatment itself.    
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Figure 3-2: Infarct size (mm3) versus size of area at risk (mm3): The infarcted volume (mm3) in the control 
hearts is clearly higher than the corresponding volume in the insulin-, GSK3β-inhibitor- and the insulin 
+ GSK3β inhibitor treated hearts, as they all lie under the regression line for the control hearts. Although there 
are variations in the area at risk, most hearts are concentrated between area of risk volumes of 1000 and 3000 
mm3. The infarct reducing effects of the treatments is not a consequence of variations in the size of the area at 
risk.     
 
3.1.3 Hemodynamic variables 
Measurements of coronary flow (CF), left ventricular developed pressure (LVDP) and heart 
rate (HR) were performed at regular intervals during the experimental protocol (Fig. 3-3). 
The four experimental groups showed no significant difference in either coronary flow or 
left ventricular developed pressure at any time point during the experiment. Still, regional 
ischemia clearly reduced cardiac function in all groups as confirmed by a substantial 
decrease in both CF (mean fall by 46%) and LVDP (mean fall by 49%), while appropriate 
reperfusion was confirmed by an increase of the same variables (Fig. 3-3). Heart rate did not 
differ significantly between the groups at any time during the experiments, with mean values 
of 278 beats/minute (BPM) at the end of stabilisation, 236 BPM at 25 minutes of ischemia 
and 259 BPM at the end of reperfusion.   
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Figure 3-3: Coronary flow, left ventricular developed pressure and heart rate during the experiments:  The 
four represented groups are: Control, 15 min insulin at reperfusion,  15 min GSK3β inhibitor at 
reperfusion, 15 min insulin + GSK3β inhibitor at reperfusion. No statistical difference was found between 
the four groups in either coronary flow (CF), left ventricular developed pressure (LVDP) or heart rate (HR) at 
any timepoint of the experiment. However, a significant decrease in both CF and LVDP in the regional 
ischemic phase was observed for all groups (*p<0.05), followed by an increase of the same variables upon 
reperfusion. Heart rate remained relatively stabile throughout the whole experiments in all four groups. 
Although a slight decrease in HR during the ischemic phase was observed, the differences were not statistical 
significant.  
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3.2 Immunoblot analysis – phosphorylation of Akt 
As already described, insulin is known to phosphorylate the prosurvival kinase Akt at Ser 
473. Baseline hearts perfused with 0.3mU/mL insulin for 20 minutes (InsulinBL) showed a 
high degree of Akt phosphorylation compared to baseline control hearts perfused with 
Krebs-Henseleit buffer (ControlBL), as demonstrated in the Western Blot in Figure 3-4A. 
GSK3β-inhibitor baseline hearts were perfused with 3μM GSK3β-inhibitor for 20 minutes, 
resulting in a very low Akt phosphorylation. Regional ischemia followed by 15 minutes of 
reperfusion, clearly increases the level of phospho- Akt (p- Akt) in control hearts 
(ControlRep), with an even stronger activation in the various groups given treatment for 15 
minutes at the onset of reperfusion (InsulinRep , GSK3β-inhRep and Insulin+GSK3β- inhRep). 
Figure 3-4B is an example of a densometric analysis of the Western Blot bands. Due to time 
limitations, the Western Blot data were not completed, and further tissue isolation and 
immunoblotting is therefore required to draw any precise conclusion.  
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Figure 3-4: The effect of insulin and GSK3β inhibition on Akt phosphorylation:  A): A representative 
Western Blot showing the effect of insulin and GSK3β inhibition on Akt phosphorylation. Baseline (BL) hearts 
were perfused with either Krebs-Henseleit buffer (ControlBL), 0.3 mU/ml Insulin (InsulinBL) or 3μM GSK3β 
inhibitor for 20 minutes. Reperfused (Rep) hearts underwent 30 min of regional ischemia, followed by 15 min 
of reperfusion with either Krebs-Henseleit buffer (ControlRep), insulin (InsulinRep, 0.3mU/mL), GSK3β 
inhibitor (GSK3β-inhRep, 3μM) or insulin + GSK3β inhibitor (Insulin + GSK3β- inhRep). B): Densometric 
analysis of Western Blot showing Akt phosphorylation, expressed in arbitrary units (AU) with ControlBL = 1.   
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4. Discussion 
This discussion section has been divided into two parts, where of the first part will concern 
the central findings of the present study and the second part comprises methodological 
considerations.   
4.1 Discussion of central findings  
4.1.1 Summary of main results 
Although reperfusion is required to salvage ischemic myocardial cells from cell death, 
reperfusion of the occluded artery per se can induce myocardial damage, a phenomenon 
termed lethal reperfusion injury. In this study we aimed to test whether three various 
pharmacological treatments could reduce the extent of reperfusion injury caused by 
myocardial ischemia in female rat hearts. We demonstrate that either administration of 
insulin, the GSK3β inhibitor (SB-415286) or the combination of both, offers 
cardioprotection in terms of reducing infarct size by 35, 36 and 41% in the ex vivo isolated 
female rat heart. In order to reveal the signalling pathways involved in this cardioprotection, 
phosphorylation status of the prosurvival kinase Akt was investigated, suggesting that Akt is 
involved in the intracellular cytoprotective cascade following insulin therapy at ischemic 
reperfusion.  
4.1.2 The cardioprotective effect of insulin 
Dosage (0.3 mU/mL) and timing of our insulin administration was taken from previous 
dose-response studies in our group performed on the male rat heart [14]. Administration of 
insulin for 15 minutes at the onset of reperfusion, following an ischemic event, induces a 
significant reduction in infarct size in the ex vivo isolated female rat heart by 35% as 
compared to control. The same degree of cardioprotection is observed in male rat hearts 
(unpublished data by A.Wergeland performed in parallel to the current study). In addition, 
previous work by Jonassen et al. demonstrates the cardioprotective effect of insulin both in 
cardiomyocytes, Girardi cells and in ex vivo isolated male rat hearts [14, 16, 17, 27]. 
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Consequently, the main finding in this part of the study is that insulin appears to protect the 
female myocardium to the same extent as the male rat hearts.  
The mechanism by which insulin exerts its cardioprotective effect is investigated by many 
researchers [14, 47, 48]. As previously described, myocardial ischemia causes an abrupt 
increase in [Ca2+] followed by mitochondrial damage and myocardial contracture [3]. One of 
the underlying causes is known as increased release of endogenous catecholamines in the 
ischemic myocardium, stimulating β-adrenergic receptors [49]. A study by Yu et al. suggests 
that the cardioprotective effect of insulin is due to its ability to counteract this β- adrenergic 
action and thereby preventing the increase in intracellular [Ca2+] [47]. Moreover, insulin has 
been shown to increase glucose uptake in the ischemic myocardium [48], and by this 
contributing to glycolysis which is important to achieve functional and metabolic recovery 
after an ischemic event [50]. However, studies by Jonassen et al. suggest that insulin-
mediated cardioprotection is independent of glucose at reperfusion [14]. Furthermore, results 
from the same study demonstrate that insulin has to be present at the immediate onset of 
reperfusion to exert its cardioprotection, and that this effect is mediated via the anti-
apoptotic PI3K/Akt signalling pathway [14]. Our study supports these findings by conferring 
cardioprotection also in female rat hearts and by demonstrating the involvement of the 
prosurvival kinase Akt when insulin was administered at the onset of reperfusion. 
Results presented in Figure 3-4 illustrate that perfusion of the isolated female rat heart with 
insulin both at baseline (InsulinBL) and reperfusion (InsulinRep), stimulates phosphorylation 
of Akt compared to their respective controls. However, previous studies in our group show a 
higher degree of Akt phosphorylation in insulin treated baseline male hearts [14], which 
serve as the main aberration from our results. Possible reasons for this difference remain 
uncertain, although one could speculate that female hearts are less responsive to insulin 
activated Akt phosphorylation at baseline. However, contradictory results from Camper- 
Kirby et al. demonstrate indeed a higher level of phosphorylated Akt in female mice 
compared to male [51]. Thus, it is likely to believe that other factors, such as methodological 
issues or too few parallels (n), contribute to the reduced insulin mediated Akt 
phosphorylation in our experiments, compared to previous studies. Clearly, further 
experiments needs to be done to elucidate this aberration.  
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Interestingly, our results demonstrate that ischemia/reperfusion in itself phosphorylates Akt 
(ControlRep), which is also supported by previous studies [14, 28]. Comparison of the 
ControlRep–hearts with the insulin treated hearts (InsulinRep) show a higher extent of Akt 
phosphorylation in the latter group, hence, we can deduce that insulin causes an additional 
activation of the PI3K/Akt signalling pathway compared to ischemia/reperfusion in itself. 
Although the downstream targets of this pathway are not fully understood, its prosurvival 
effect has been demonstrated, and thus represents an explanation of insulin’s 
cardioprotective effect.   
4.1.3 The cardioprotective effect of GSK3β- inhibition  
Results from the present study demonstrate that administration of the GSK3β-inhibitor SB-
415286 for 15 minutes at the onset of reperfusion, significantly reduce infarct size in the ex 
vivo isolated female rat heart by 36% as compared to control. The same degree of 
cardioprotection is observed in male rat hearts (unpublished data by A.Wergeland). The 
GSK3β-inhibitor SB-415286 dose was set to 3μM, which compared to other studies [22, 52], 
is a lower dose (i.e. Das et al. used 10μM at Langendorff perfused rat hearts, although not 
investigating effects on infarct size). However, as our dose of 3μM conferred 
cardioprotection we continued to use it throughout the experiments. Recent and independent 
studies have also shown that inhibition of GSK3β offers cardioprotection in cardiomyocytes 
[22], in situ rat hearts [43] and in isolated ex-vivo guinea pig hearts [44]. Consistent with 
these findings, and in concordance to the studies done by Gross et al. on in vivo male rat 
hearts [23, 42], we demonstrated the ability for the GSK3β-inhibitor SB-415286, to reduce 
infarct size in the ex vivo isolated female rat heart.  
Results illustrated in Figure 3-4 demonstrate that administration of the GSK3β inhibitor SB-
415286 to female baseline rat hearts (GSK3β-inh.BL) causes low Akt phosphorylation. This 
result was expected, as GSK3β is known to be downstream of Akt [42], and therefore the 
phosphorylation status of Akt will not be influenced by direct inhibition of GSK3β. On the 
other hand, female rat hearts subjected to regional ischemia followed by 15 minutes of 
GSK3β inhibitor treatment (GSK3β-inh.Rep) showed an increased Akt phosphorylation 
compared to GSK3β-inhibitor baseline hearts. It is reasonable to believe that this effect is 
mediated by ischemia/reperfusion itself, as we have shown that GSK3β inhibition do not 
influence the phosphorylation status of Akt. Hence, we would expect that hearts treated with 
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GSK3β-inhibitor for 15 minutes at reperfusion (GSK3β-inh.Rep) would have the same level 
of phosphorylated Akt as control hearts only being subjected to regional ischemia 
(ControlRep). The explanation why our GSK3β-inh.Rep hearts show a higher degree of Akt 
phosphorylation (almost as high as InsulinRep-hearts) compared to ControlRep-hearts is 
uncertain, yet it is likely to believe that methodological factors might have influenced the 
results (discussed later).   
The knowledge about the precise mechanism by which GSK3β inhibition is cardioprotective 
remains incomplete, however, the mitochondrial permeability transition pore (mPTP) is 
hypothesized as an important target [22, 40]. The mPTP will open during reperfusion [53], 
and by inhibiting this opening, one will prevent influx of solutes and water, swelling and 
bursting of the mitochondrial matrix and thus hinder pro-apoptotic factors leaking into the 
cytosol [21]. Interestingly, Davidson et al. have shown that insulin also mediates inhibition 
of the mPTP through activation of the PI3K/Akt signalling pathway [54]. Still, the 
mechanism or the link between the prosurvival kinases and the mPTP remains unclear. 
Various mechanisms are suggested, where insulin mediated phosphorylation and inhibition 
of GSK3β is described as one of them (Fig. 1-6) [22, 54]. Hence, this serves as a possible 
explanation for the cardioprotective effect observed with both insulin and GSK3β-inhibitor 
treatment in the current study.  
The exact interaction between GSK3β and the mPTP is not completely understood. 
However, Das et al. suggest a possible association with adenine nucleotide transport through 
voltage-dependent anion channels (VDAC), which are a component of the mPTP [52]. Their 
results demonstrate that GSK3β inhibition reduce the adenine nucleotide entry into the 
mitochondria by dephosphorylation of the mPTP, with likely consequences of lessening both 
mitochondrial calcium loading during anoxic conditions, as well as reducing endogenous 
oxygen radical production during reoxygenation/reperfusion [52]. In addition, data from the 
same study implies that GSK3β-inhibitors cause an increased affinity for the anti-apoptotic 
protein Bcl-2 to the mPTP, a result supported by Juhaszova et al. [22]. Consequently, both 
reduced calcium loading, reduced oxidative stress and more Bcl-2 binding to the mPTP are 
described as contributors to the cardioprotective effect of GSK3β-inhibitors [52]. 
Other theories are also described in the literature aiming to explain the cardioprotective 
effect of GSK3β-inhibition. One of the downstream targets of GSK3β is the oxygen 
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regulated Hypoxia-inducible transcription factor 1α (HIF-1α) [55]. This transcription factor 
is virtually undetectable in cells at normal oxygen levels, but will accumulate at low oxygen 
levels (hypoxia), resulting in increased transcription of various genes [55]. Active GSK3β is 
described to down-regulate protein levels of HIF-1α by initiating its degradation through 
phosphorylation [56]. Schnitzer et al. also reports that inhibition of GSK3β by the powerful 
inhibitor indirubins, reverse HIF1α depletion under prolonged hypoxia/anoxia [57]. As 
intracellular HIF1α-levels increase, a stimulation of gene-transcription will occur, where one 
of the regulated genes are coding for the adipocytokine apelin [58]. More specifically, 
Ronkainen et al. demonstrated that increased levels of HIF1α induce apelin expression in rat 
myocardium and in cultured cardiomyocytes [59]. Apelin is reported as cardioprotective by 
reducing infarct size after myocardial ischemia through increasing the phosphorylation status 
of Akt and MAPK [60, 61], and interestingly also by delaying the opening of the mPTP [61]. 
Based on these findings, it seems likely that both HIF1α and apelin might be contributors to 
the cardioprotective effect of GSK3β-inhibition. In addition, preliminary results from our 
own group have shown an increase in apelin mRNA at 120 minutes of reperfusion during 
insulin therapy (unpublished data by Mari Johansen), suggesting a possible role for apelin 
also in insulin mediated cardioprotection.    
4.1.4 The cardioprotective effect of the co-treatment with insulin and 
GSK3β- inhibitor 
The PI3K/Akt signalling pathway, which is activated by insulin, has shown to inhibit 
GSK3β by phosphorylation. By combining insulin treatment with a pharmacological, direct 
inhibitor of GSK3β (SB-415286), we hypothesised a synergistic cardioprotective effect 
compared to the two treatments given alone. A search on PubMed reveals no previous 
studies where combinational treatment with insulin and GSK3β-inhibitor has been tested. 
Therefore our study demonstrates a new approach in finding cardioprotective therapy against 
ischemic-reperfusion injury.   
Our results show a significant decrease in infarct size when the co-treatment of insulin and 
GSK3β-inhibitor were administrated for 15 minutes at the onset of reperfusion to ex vivo 
female rat hearts (Fig. 3-1). Yet, this treatment shows no additional reduction in infarct size 
compared to the single treatments alone. The same results are observed in male rat hearts 
(unpublished data by A.Wergeland). 
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The reason why no additional cardioprotective effect is observed with the co-treatment 
remains uncertain, although a maximum saturation and inhibition of the GSK3β enzyme 
either by insulin or the direct inhibitor SB-415286 might be a possible explanation. This 
intensifies the hypothesis that the cardioprotective effect of insulin and the GSK3β-inhibitor 
is mediated via the same signalling pathway. However, as insulin and the GSK3β-inhibitor 
are reported to inhibit GSK3β via two distinct mechanisms, through phosphorylation and 
blocking of ATP binding respectively [62], one could assume that additive inhibition would 
be possible. Hence, the dose of the GSK3β-inhibitor used in the experiments might have 
influenced the results, as we have used a lower dose compared to others [22, 52]. Further 
experiments, including a dose-response study with the GSK3β-inhibitor, are required to 
clarify this question.  
Western Blot results demonstrate a similar degree of Akt phosphorylation in female rat heart 
treated with either insulin or insulin+GSK3β-inhibitor (Fig. 3-4). As insulin is the factor that 
mediates phosphorylation of Akt, and the direct GSK3β-inhibitor acts downstream, this 
result is expected.   
4.1.5 Cardioprotection in female versus male rat hearts 
The prevalence and incidence of ischemic heart disease (IHD) at all ages are higher in males 
than in females. However, due to the larger female population beyond 75 years, the absolute 
number of elderly women with IHD overcomes the number of males [5]. Compared to men, 
women with all types of IHD are older, have more vascular risk factors and co-morbidities 
and thereby represent a high risk group [5]. It is also reported that females with acute 
coronary syndromes have more atypical symptoms [5] and appear to be relatively better 
protected from sudden death outside hospital [6]. All this has resulted in an increased focus 
on women and cardiovascular disease in the setting of medical research. Based on this, one 
of the main aims of this study was to investigate whether various reperfusion treatments 
conferred different response in female compared to male rat hearts. Nevertheless, treatments 
with insulin, GSK3β-inhibitor or the combination of the two, demonstrates no sex 
differences in terms of cardioprotection, when comparing my results with parallel data from 
male rats collected by A.Wergeland (unpublished, 2009).  
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Certain diseases, diet, smoking and genetics are all known risk factors of cardiovascular 
disease [5], however estrogen has by some researchers been outlined as an important 
contributor to the higher protection against cardiovascular disease observed in women [4, 
63]. The rats used in this study were between 11-14 weeks, and as the age of puberty in 
female rats are between the 6th and 11th week [64], we can expect normal estrogen levels in 
our experimental animals. The female sex hormone is reported as cardioprotective both 
through rapid and long-term effects on blood vessel walls [4], as well as activating the 
prosurvival PI3K/Akt signalling pathway following acute ischemia [63, 65]. Whether these 
effects contribute to the reduced infarcts seen in our experiments is uncertain, as we have 
performed experiments on ex vivo isolated rat hearts. The KHB-buffer used to perfuse our 
hearts, did not contain estrogen, hence the hearts are not exposed to the same hormone 
concentrations as in an in vivo situation. Yet, the overall role of estrogen in cardioprotection 
remains to be fully confirmed, as results from clinical trials demonstrated no 
cardioprotective effect of hormone replacement therapy on postmenopausal women [66].  
4.2 Methodological considerations 
4.2.1 The isolated ex vivo Langendorff perfused rat heart 
4.2.1.1 Anaesthesia 
In this study the rats were given Pentobarbital (i.p.) which is a widely used anestheticum. As 
for all anaesthetics, a potential harm is its influence on experimental parameters, like 
hemodynamic recordings and infarct size. Pentobarbital is shown to cause an increase in 
vascular resistance and a reduced cardiac output in rats [67]. In our ex vivo model system 
these effects are probably not relevant, as the vascular resistance is more dependent on the 
perfusion pressure from the system. Additionally, the heart is cannulated through the aorta, 
making measurements of the cardiac output impossible. Yet, most importantly Pentobarbital 
is demonstrated not to influence infarct size or react with TTC staining [46].   
4.2.1.2 The Langendorff heart model  
The isolated Langendorff heart perfusion method was first described more than hundred 
years ago [68], and is still a widely used method in basic cardiac research, due to its 
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simplicity, high reproducibility and relatively low cost. With the ability to study both 
biochemical, physiological, morphological and pharmacological factors, a large amount of 
information can be gained in a relatively short time. Temperature and perfusion pressure of 
the system can be easily controlled, as well as the ion-, substrate- and drug content of the 
perfusion medium. As the heart is completely isolated, confounding effects like circulating 
neurohormonal factors and the influence from sympathetic and vagal stimulation are 
avoided, exclusively allowing the investigation of the cardiac response to our interventions 
[45]. Simultaneously, this can also be considered as a disadvantage with the heart not being 
exposed to the same environment as in an in vivo situation. 
Krebs Henseleit buffer, used as perfusion fluid in this experiment, has the same ionic content 
as ordinary blood, and contains glucose as energy source. Under normal physiological 
conditions (in vivo) most of the ATP is produced by oxidation of fatty acids. However, 
dissolution of fatty acids and albumin are difficult to perform in an aqueous solution, and is 
the main reason why glucose is used as primary energy source in this model [45]. Absence 
of erythrocytes gives a reduced oxygen carrying capacity and leads to a higher coronary flow 
rate compared to in vivo situations. Even so, the isolated Langendorff perfusion method 
provides an excellent test- bed for pharmacological dose- response studies as well as the 
assessment of arrhythmias, ischemia- and reperfusion induced injury [45]. 
4.2.1.3 Infarct size measurements 
Infarct size is the major end point in the present study, thus validation of methodological 
issues concerning infarct size determination, is important.  To compare infarct size between 
the experimental hearts, variations of the ischemic risk zones (area at risk) should be 
minimized, as larger risk zones could cause larger infarctions. Due to small variations in the 
anatomy of the coronary vasculature in the rat, it is possible to overcome this, and as 
presented in Figure 3-2, no significant difference in risk area is found between our various 
experimental groups. Hence, we can conclude that the infarct reducing effects of the 
treatments is a consequence of the therapy itself, rather than variations in the size of area at 
risk. 
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A histochemical method based on triphenyl tetrazolium chloride (TTC)-staining was used to 
separate viable from non-viable myocardial tissue. As TTC reacts with dehydrogenase 
enzymes and cofactors present in viable cells, a deep red colour develops. Non-viable cells 
lack these enzymes, and dead myocardium will therefore remain unstained, appearing 
grey/white. Drawbacks with the TTC staining method is its lacking ability to stain scattered 
cell damage, as well as its potential interference with pharmacological agents [46]. Although 
reaction between TTC and the agents used in this study can not be excluded, the short period 
of administration (15 minutes) followed by a wash-out period of 2 hours (reperfusion), 
reduce the probability of such interference.     
4.2.1.4 Hemodynamic variables 
Hemodynamic parameters, such as heart rate (HR), left ventricular systolic (SP), diastolic 
(DP) and developed pressure (LVDP) were measured by inserting a compliant balloon 
connected to a pressure transducer, into the left ventricle. Great care must be taken while 
inserting the balloon, as heart tissue easily can be damaged. Although the Working Heart 
preparation is a more suitable method for evaluating functional recovery (such as pump 
function) [45], our measurements of developed pressure still function as a useful validation 
of our experimental protocol. Figure 3-3 illustrates this by a clear reduction in cardiac 
function at the onset of regional ischemia, confirmed by a decrease in both LVDP and 
coronary flow (CF); while appropriate reperfusion is confirmed by an increase of the same 
variables. Furthermore, no significant differences are found in either LVDP, CF or HR 
between the four experimental groups at the given timepoints, hence we can deduce that the 
observed differences in infarct size is not due to hemodynamic variations.   
4.2.2 Immunoblotting 
Immunoblotting comprises the isolation and homogenisation of heart tissue, protein 
estimation and finally Western Blotting. Many steps are involved in these processes, making 
the number of potential sources of error high. First of all, the isolation of cardiac tissue is a 
critical point, as phosphorylation/dephosphorylation of proteins can easily be influenced. 
Our protein of interest (p-Akt) can easily dephosphorylate at high temperatures, thus rapid 
freezing is essential. Inaccuracy during this step could be an explanation to our somewhat 
varying Western Blot results observed in the present study, i.e. the reduced Akt 
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phosphorylation in InsulinBL hearts as compared to previous studies [14]. Also, temperature 
control during the tissue homogenisation is important to prevent protein dephosphorylation, 
and the samples were therefore kept on ice. Still, as disintegration of the tissue by the 
Precellys was not possible to perform in a cold environment, we can not exclude this as a 
potential error.  
Main sources of errors in the Western Blot protocol are unequal loading of proteins onto the 
gel, inadequate transfer of proteins from the gel to the PVDF membrane, as well as issues 
concerning detection of the proteins. As loading control, levels of total Akt should have been 
analysed to verify equal amounts of protein in each lane; however, due to time limitations 
this step was not performed. During this study, a lot of time has been used in optimizing 
each step of the protocol, especially in regard to the transfer process and determination of 
antibody concentrations. Although we finally gained clear Western Blots with distinct bands, 
the strength of the bands is not all as expected, compared to previous results in our lab. 
Consequently, it is more likely to believe that methodological issues previous to the Western 
Blotting, such as temperature dependant dephosphorylation of proteins, might have 
influenced our result.      
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4.3 Conclusions 
The main objectives in the present study was to investigate whether treatment with insulin, 
the GSK3β-inhibitor SB-415286 or the combination of the two, administrated for 15 minutes 
at the onset of myocardial-ischemic reperfusion, could reduce infarct size in the isolated ex 
vivo female rat heart. Furthermore, the phosphorylation status of the prosurvival kinase Akt 
was examined in the treated hearts.  
 
1. Treatments with insulin, GSK3β-inhibitor (SB-415286) or the combination of 
the two, administrated for 15 minutes at the onset of ischemic reperfusion, 
significantly reduce infarct size in the ex vivo isolated female rat heart.  
2. No synergistic cardioprotective effect, in terms of reducing infarct size, is 
observed with co-treatment of insulin and the GSK3β-inhibitor SB-415286, 
compared to the two treatments alone.   
3. No difference in infarct size is discovered between female and male rats when 
given the various treatments described above (experimental data collected in 
male rat hearts by A.Wergeland).  
4. Preliminary data suggest that phosphorylation of the prosurvival kinase Akt is 
involved in insulin mediated cardioprotection in the female rat heart. However, 
its phosphorylation status is not affected by treatment with GSK3β-inhibitor.  
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4.4 Future perspectives 
4.4.1 Further studies 
The present study opens for many further study approaches. First of all, a dose response 
study with the GSK3β-inhibitor SB-415286 should be performed to investigate whether a 
more pronounced degree of cardioprotection could be obtained with higher doses. In 
addition, our data demonstrating the cardioprotective effect of insulin, GSK3β-inhibitor, and 
the combination of the two, should be verified through in vivo experiments, to evaluate 
potential harmful and toxic effects.   
As already mentioned, our Western Blot results are preliminary, hence several experiments 
assessing the phosphorylation status of Akt should be added to draw final conclusions on the 
effect of the various treatments. Additionally, phosphorylation of GSK3β and other proteins 
involved in alternative signalling pathways (i.e. p70S6K, BAD, mTOR) should be 
investigated, to get a deeper understanding of the signalling pathways mediated by insulin 
and the GSK3β-inhibitor. Another approach to increase our understanding of downstream 
mechanisms involved in this cardioprotection, is to explore the effect our treatments exert on 
the mPTP by investigating pore opening and closure, and also investigate protein levels of 
HIF1α and apelin.   
To further investigate the potential sex difference in response to myocardial ischemia, an in 
vivo model system would be suitable, as the animals then will be exposed to normal 
circulating hormone concentrations, such as estrogen. In addition, comparative studies of 
post- and pre- menopausal females would be interesting to more specifically address the 
effect of estrogen in cardioprotection.    
4.4.2 Clinical relevance 
Despite an improved management of patients with acute myocardial infarction (AMI) during 
the last decades, there is still a need for novel therapeutic strategies aiming to protect the 
myocardium from ischemic reperfusion induced injury. An advantage of the cardioprotective 
therapies used in this study is their ability to exert effect even when administrated at the 
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immediate onset of reperfusion. Insulin is a well characterised hormone where both 
beneficial-  and potential side-effects are known. Interestingly, signalling pathways involved 
in insulin mediated cardioprotection might suffer from impairment by common co-
morbidities in AMI- patients, such as diabetes [69] and post-infarct remodelling [70]. Thus, 
the use of insulin in a clinical setting might be limited. As for the GSK3β-inhibitor SB-
415286, its chemical, physical and toxicological properties have not been fully investigated; 
and further testing is therefore needed. Nevertheless, an advantage of this compound is the 
ability to directly inhibit GSK3β without interfering with upstream pathways [71], and by 
this diminish the problem with concurrent diseases, such as diabetes. Even though chronic 
inhibition of GSK3β is reported to potentially increase the risk of cancer development [72], 
it is unlikely to believe that a single injection of a GSK3β inhibitor would amount to this 
risk. Thus, GSK3β-inhibiton serves as a promising route for reducing myocardial damage in 
AMI patients.        
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Appendix A 
Buffers and solutions for Langendorff Perfusion of Rat Heart 
 
• Krebs- Heinslet Buffer for perfusion of rat hearts  
Concentration   g/5L 
118 mM     34.48 g NaCl  
25 mM     10.5 g  NaHCO3 
11 mM    9.9 g  d- Glucose  
4.7 mM   1.75 g  KCl 
1.22 mM   1.5 g  MgSO4(7H2O) 
 1.21 mM   0.825 g KH2PO4 
 2.4 mM   1.76 g  CaCl2 
 - Stored at 4°C 
 - CaCl2 dissolved in ddH2O prior to buffer to avoid precipitation  
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• Phosphate buffer (0.2 M) 
Solution 1:   
27.6 g   NaH2PO4*2H2O in 1 L ddH2O 
Solution 2:  
71.6 g   Na2HPO4*12H2O in 1 L ddH2O  
- Mix 2 parts solution 1 + 8 parts solution 2 
- pH = 7.4 
- For tissue staining: 1% triphenyl- tetrazolium- chloride dissolved in buffer 
 
 
• Formalin 
1L   Formaldehyde 
40 g  NaH2PO4 
65 g  Na2HPO4*12H2O 
ddH2O  to 10 L 
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Buffers and solutions for tissue homogenization and Western Blot 
• Lysis Buffer 
20 mM   Tris- HCl 
0.5 mM  EGTA 
1%   Triton 
300 mM  Sucrose 
2 mM   EDTA 
1x  Complete Mini EDTA- free Protease Inhibitor Tablet (1 tablet 
dissolved in 10 mL ddH2O = 1x)  
 
• Running Buffer 
BupHTM Tris (100mM) - HEPES (100mM) - SDS (3mM) Running Buffer dissolved 
in  
500 ml ddH2O 
 
• Transfer Buffer 
100 ml  10x Tris/ Glycine Buffer 
700 ml  Distilled H2O 
200 ml  Methanol  
- Stored at 4°C 
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• Tris Buffered Saline- Tween (TBS-T) – 1x 
50 ml  20xTBS (320g NaCl + 96.8g Tris, ddH2O to 2 L. pH adjusted to 7.6) 
950 ml  ddH2O 
1 ml   Tween
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Appendix B 
Calibration of pressure transducer and Power Lab 
Before the heart could be mounted onto the Langendorff perfusion system it was necessary 
to remove all air bubbles in the reservoirs and rubber tubes of the Langendorff system, to 
prevent formation of air- emboli in the heart. In addition, air bubbles had to be removed 
from the water filled balloon, the water filled plastic catheter connecting the balloon to the 
pressure transducer, and from the transducer itself as air could influence the compliance in 
the system. During the experiments, as pressure is applied to the water filled balloon by the 
contracting heart, the water column in the catheter moves, causing a physical deformation of 
a thin membrane placed inside the transducer. This membrane movement will produce a 
change in electrical resistance proportional to the applied pressure, causing an electrical 
signal (mV) which is passed on to the Power Lab. Conversion of the electrical signal (mV) 
to the actual pressure (mmHg) is done by the Power Lab and is expressed graphically on the 
computer.   
Calibration of the transducer was carried out every day before starting an experiment, by 
applying two known pressures to the transducer: 0 mmHg (atmospheric pressure) and 200 
mmHg (applied by a sphygmomanometer). The pressures were registered in the Power Lab 
and the expressed graphs were adjusted according to the calibrated results (Fig. B-1). 
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Figure B-1: Calibration of the pressure transducer. To ensure stabile pressure measurements from day to 
day, the transducer was calibrated prior to the experiments by applying two known pressures (0 mmHg and 
200mmHg) to the system. The pressure transducer converts pressures into an analogue electrical signal (mV) 
which again is converted to a pressure (mmHg) by the Power Lab. The graph illustrates this last conversion, 
where, in this case, the graph is adjusted against the pressures of 0 and 200 mmHg thereby ensuring adequate 
calibration. 
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